hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 22:38:10 - browse：5

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Awakening the world to the whoosh: A patient's crusade

hotspot

WSS

Tocagen's brain cancer gene therapy trial continues. Investors worry

Mass General totes up its waste in a move to tackle climate change

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

DeSantis talks Trump, trans issues and 'what wokeness is'

Mass General totes up its waste in a move to tackle climate change

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Cancer drug shortages should be causing more outrage

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Trump demands the U.S. pay no more for drugs than other countries … again

Why Congress must ban federal programs from using QALYs

How one medical school became remarkably diverse

Lab trade group sues FDA to halt regulation of lab

focus

First Opinion Podcast: What happens when kids become caregivers?

First Opinion Podcast: What happens when kids become caregivers?

Latest bird flu infection made farmworker sicker than earlier cases

Study identifies new proteins linked to dementia risk 25 years later

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Adam's Biotech Scorecard: Do Sarepta's exon

entertainment

hotspot

hotspot

focus